Pinnacle Bancorp’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinnacle Bancorp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.1K	Hold	54	–	–	0.01%	573
2025 Q4	$24.5K	Hold	54	–	–	0.01%	562
2025 Q3	$21.1K	Buy	+54	New	+$22.6K	0.01%	609
2023 Q2	–	Sell	-31	Closed	-$9.77K	–	813
2023 Q1	$9.77K	Hold	31	–	–	﹤0.01%	624
2022 Q4	$9K	Hold	31	–	–	﹤0.01%	593
2022 Q3	$9K	Sell	31 -29	-48%	-$8.34K	﹤0.01%	578
2022 Q2	$17K	Hold	60	–	–	0.01%	480
2022 Q1	$16K	Sell	60 -194	-76%	-$46K	0.01%	519
2021 Q4	$56K	Hold	254	–	–	0.02%	338
2021 Q3	$46K	Hold	254	–	–	0.02%	356
2021 Q2	$51K	Buy	254 +15	+6%	+$3.14K	0.02%	350
2021 Q1	$51K	Buy	+239	New	+$52.5K	0.02%	341
2017 Q1	$87K	Buy	+800	New	+$70.4K	0.06%	208

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pinnacle Bancorp's VRTX Position: Q1 2026 in Review

Pinnacle Bancorp held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 54 shares worth $24.1K. The position accounts for 0.01% of the portfolio, ranked #573.

Pinnacle Bancorp first reported a position in VRTX in Q1 2017 and has held it in 13 quarters since. The position peaked at $87K in Q1 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Pinnacle Bancorp held 54 shares of Vertex Pharmaceuticals worth $24.1K as of Q1 2026.
Pinnacle Bancorp left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Pinnacle Bancorp's portfolio in Q1 2026, its #573 holding.
Pinnacle Bancorp first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
Pinnacle Bancorp's Vertex Pharmaceuticals position peaked at $87K in Q1 2017.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Pinnacle Bancorp's 13F filing for Q1 2026, filed 22 Apr 2026.